Dec 22, 2025

PGxAI and Mahd Sports Academy announce strategic partnership to advance AI‑enabled sports genomics across Saudi Arabia

Sports | Published: Dec 22, 2025

news image

RIYADH, Saudi Arabia — PGxAI and Mahd Sports Academy are partnering to bring advanced genetics and AI to athlete development and performance across the Kingdom. The collaboration aims to accelerate personalized training, reduce preventable injuries, and uphold national standards for data governance and security.

The parties intend to build an in‑country capability that responsibly integrates genetic, phenotypic, and biometric signals into secure analytical workflows for coaches, clinicians, and performance teams.

Data generated under the program will be stored within Saudi Arabia and managed in accordance with the Personal Data Protection Law, ensuring that insights are developed and retained in‑Kingdom.

“Sports performance is inherently multi‑factorial,” said Mike Zack, MD, PhD, Co‑Founder & CEO of PGxAI. “By responsibly integrating genetics with real‑world performance data, we can help teams individualize training, reduce risk, and unlock peak potential at scale.”

For athletes, the partnership is designed first and foremost to support well‑being and performance. Participation is voluntary and consent‑based; insights are communicated in plain language and used to assist in training and care planning.

The program emphasizes injury prevention, safe return‑to‑play pathways, and equitable access across men’s and women’s disciplines, with dedicated education for athletes, coaches, and families.

The collaboration complements PGxAI’s broader regional strategy with Najashi Holding to localize cutting‑edge precision‑health platforms in support of Saudi Arabia’s Vision 2030 and Health Sector Transformation Program.

Together, the organizations will pursue training, technology transfer, and research initiatives that cultivate enduring expertise and position the Kingdom at the forefront of sports science and human performance.

“At Najashi Holding, our mission is to build the foundation for a future where innovation, technology, and human performance advance together,” said Ibrahim Najashi, MD, Chairman of Najashi Holding. “By investing in strategic collaborations that enhance data stewardship, local capability, and applied science, we aim to enable Saudi Arabia to lead the next frontier of deep health-tech and precision sports innovation.”

As the partnership progresses, the parties plan to align platform architecture, governance, and clinical‑performance pathways that can be deployed within leading sports institutions nationwide. The program is expected to catalyze new research, enable role‑based decision support for coaches and medical teams, and establish a sustainable foundation for Saudi‑specific insights and innovation.

About PGxAI

PGxAI is advancing precision medicine by addressing drug selection and dosage optimization with unmatched accuracy and reproducibility. By integrating AI, multiomics, and real-world evidence, the company enables clinicians and health systems to deliver safer, more effective, and personalized therapies.

Founded by Mike Zack, MD, PhD, MPH — a pharmacogenomics scientist ranked among the world’s top 1% by citations (Elsevier 2025) — and Allan Gobbs, a life sciences entrepreneur with nine exits including five IPOs, PGxAI collaborates with leading partners such as Google Cloud, Microsoft, Nvidia, AWS, InterSystems, MIT (MIMIC-IV), NIH (All of Us), UF Health, the University of British Columbia, and the Ministries of Sport and Health of Saudi Arabia.

About Najashi Holding

Najashi Holding is a Riyadh-based investment and management firm that focuses on Healthcare and Biotechnology investments. Aligned with Saudi Vision 2030, the firm drives economic diversification and innovation by forging strategic partnerships with leading global companies and accelerating the growth of high-impact industries across Saudi Arabia and the GCC. Leveraging deep market knowledge and an extensive public- and private-sector network, Najashi Holding plays a pivotal role in advancing the Kingdom’s healthcare transformation and positioning the region as a hub for technological and industrial leadership.

Zawaya: https://www.zawya.com/en/press-release/companies-news/pgxai-and-mahd-sports-academy-announce-strategic-partnership-to-advance-aienabled-sports-genomics-across-saudi-arabia-hn9qd7bc

Success Stories
Serving Every Stakeholder in Healthcare
image
Press Release
Jan 21, 2026
PGxAI and Novo Genomics scale AI‑enabled pharmacogenomics across Saudi Arabia
image
Press Release
Dec 22, 2025
PGxAI and Mahd Sports Academy announce strategic partnership to advance AI‑enabled sports genomics across Saudi Arabia
image
Event
Nov 1, 2025
PGxAI Selected as a Finalist at the HLTH USA 2025 Startup Pitch Tournament
image
Press Release
Oct 13, 2025
PGxAI and Najashi Holding partner to advance precision medicine in Saudi Arabia
image
News
Oct 1, 2025
PGxAI Welcomes Roni Zeiger as Product Strategy Advisor
image
News
Sep 18, 2025
PGxAI Admitted to Creative Destruction Lab (CDL) Seattle — Computational Health 2025–2026
image
News
Sep 3, 2025
PGxAI Welcomes John Quackenbush as Scientific Advisor
image
Press Release
Aug 19, 2025
PGxAI and Sequencing.com Announce Strategic Partnership to Advance Affordable Pharmacogenomics
image
News
Aug 16, 2025
PGxAI Named a Key Player in Straits Research’s Pharmacogenomics (PGX) Market Report
image
News
Aug 3, 2025
PGxAI Welcomes David Blumenthal as Scientific Advisor
image
News
Jul 18, 2025
Benchmarking LLMs for Pharmacogenomic (PGx) Recommendations
image
News
July 04, 2025
AI & Multi-Omics in Pharmacogenomics: PGxAI’s New Review
image
Press Release
Jun 27, 2025
PGxAI Unveils Betelgeuse — New AI Model for Real-Time Clinical Outcome Analysis and Adaptive Recommendations
image
News
Jun 14, 2025
Upload Your Own Genetic Data: Instant Drug-Sensitivity Insights Now in All Base Models
image
News
May 16, 2025
Drug-Drug Interaction Module—FDA-Label Powered, Terminal-Ready—Now Live in All Open Models
image
News
Apr 23, 2025
PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Drugs Including Ozempic®
image
News
Apr 15, 2025
PGxAI Debuts Deneb, an AI Model Revolutionizing Drug Development for Biopharma
image
News
Mar 16, 2025
Automated Phenoconversion Arrives: Real-Time, Context-Aware Drug-Response Scoring in Every Base Model
image
News
Feb 28, 2025
PGxAI Debuts Vega, an AI Model Set to Disrupt Precision Medicine
image
Press Release
Dec 24, 2024
Revolutionizing Precision Medicine: PGxAI Raises $1.5 Million in Funding for AI-Powered Pharmacogenetics Platform
image
News
Dec 21, 2024
The Ventures Award: The World's Premier Stage for Startup Excellence
image
Press Release
Dec 19, 2024
PGxAI Launches Sirius, an AI‑Powered Pharmacogenetics Model
image
Press Release
Jun 25, 2024
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration